ASBM Releases Fact Sheets on Interchangeable Biosimilars

November 30, 2023

In November, ASBM released two fact sheets on interchangeable biosimilars. Download them here: Physician Perspectives on Interchangeable Biosimilars Interchangeable Biosimilars: Comparing Europe and the U.S.

Read More


ASBM Letter to Congress Defends Interchangeability Standard

September 27, 2023

In a letter to Senator Mike Lee (R-UT) dated September 27th, ASBM urged the Senator to reconsider his support for S.6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable”. Under U.S. state law, only interchangeable biosimilars are substitutable at the […]

Read More


Medicare Price “Negotiations” Will Jeopardize Patient Access to New Medicines, Result in Worse Health Outcomes

September 11, 2023

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. Over the next 4 years, Medicare will set prices for up to 60 drugs covered under Medicare […]

Read More


ASBM/IFA Survey: As Ontario Announces Forced Biosimilar Switching, Ophthalmologists Are Latest Specialty to Raise Concerns

February 28, 2023

Press Release: As Ontario Announces Forced Biosimilar Switching, Ophthalmologists Are Latest Specialty to Raise Concerns 28 February 2023 TORONTO, ONTARIO – Physicians and their patients- and not a government -should choose which biologic medicine to use, according to a new survey of Canadian ophthalmologists by the Alliance for Safe Biologic Medicines (ASBM) and the International […]

Read More


ASBM Welcomes Ralph McKibbin, MD as Chairman

September 9, 2021

ARLINGTON, VA- In a Full Member Call today the Alliance for Safe Biologic Medicines (ASBM) introduced gastroenterologist Ralph McKibbin, MD, FACP, FACG, AGAF as the organization’s incoming chairman. Dr. McKibbin began his three year term on September 1st, succeeding outgoing chair Madelaine Feldman, MD, FACR. Dr. McKibbin will be the fourth chairman since ASBM was founded in […]

Read More


New White Paper To Detail European Biosimilar Evolution and Policy Principles

November 9, 2019

November 6, 2019 – Gatineau, Quebec – The Alliance for Safe Biologic Medicines (ASBM) today released an abstract from a forthcoming white paper that provides a comprehensive overview of the evolution of the European biosimilars market.  The abstract was released in conjunction with the Drug Information Association (DIA) Annual Canadian Meeting, an annual meeting of […]

Read More


ASBM Releases Preliminary Findings from European Prescribers Survey at ESMO 2019

October 1, 2019

September 30, 2019 – Barcelona, Spain – The Alliance for Safe Biologic Medicines (ASBM) this week shared preliminary findings from a survey of 575 biologic prescribers in six Western European countries, covering several key policy issues including biosimilar substitution practices, adverse event reporting, and government tendering criteria. Since 2010, the group has routinely surveyed physicians […]

Read More


Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative

September 23, 2019

Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative VANCOUVER, BC – Wednesday, September 18, 2019. On September 5, 2019, the BC government announced phase two of its Biosimilars Initiative, informing patients prescribed the originator biologic drug, Remicade® (infliximab), to treat inflammatory bowel disease (Crohn’s disease and ulcerative colitis) that this medication […]

Read More


ASBM Raises Concerns for Patients as BC Gov’t Expands Biologics Forced-Switching Policy

September 11, 2019

Erosion of Physician and Patient Treatment Choice Continues – Alliance for Safe Biologic Medicines Raises Concerns for Patients as British Columbia Expands Biologics Forced Switching Policy September 10, 2019   VANCOUVER, B.C.- On September 5th, the Government of British Columbia (BC) announced that it would be forcibly switching 1,700 patients with Inflammatory Bowel Disease (IBD) […]

Read More


ASBM Releases Fact Sheet on British Columbia vs EU Substitution Policies

August 5, 2019

As BC attempts to increase biosimilar use by force-switching 23,000 patients, Europe enjoys high uptake rates while preserving patient and physician choice.  On August 5th, ASBM released a fact sheet contrasting the biosimilar substitution policies of European countries (which generally have robust biosimilar markets) with the newly announced British Columbia policy. First fact sheet also addresses misconceptions […]

Read More